反应详情

6-(4-Methoxybenzyl)-9-(oxiran-2-yl)pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one (118 mg, 0.337 mmol) was treated with morpholine (0.50 mL) and stirred for 16 h at room temperature. The mixture was concentrated under vacuum, re-dissolved in DMSO, and filtered. Purification (HPLC, elution with 20 to 80% acetonitrile in water) afforded the title compound (63 mg, 26%) as the TFA salt as a white powder. 1H NMR (400 MHz, CDCl3) δ 3.11 (br s, 4H), 3.26 (dd, J=13.30, 2.89 Hz, 1H), 3.35 (dd, J=13.30, 10.67 Hz, 1H), 3.76 (s, 3H), 4.12 (br s, 4H), 5.65-5.71 (m, 1H), 5.73 (s, 2H), 6.82 (d, J=8.78 Hz, 2H), 7.58 (d, J=8.66 Hz, 2H), 8.35 (s, 1H), 8.69 (d, J=2.26 Hz, 1H), 8.90 (d, J=2.26 Hz, 1H). [M+H]=437.2.

1. concentrationThe mixture was concentrated under vacuum
2. dissolutionre-dissolved in DMSO
3. filtrationfiltered
4. customPurification (HPLC, elution with 20 to 80% acetonitrile in water)